{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:37:32Z","timestamp":1787027852056,"version":"build-2736575974"},"reference-count":222,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>An accurate estimation of AML prognosis is complex since it depends on patient-related factors, AML manifestations at diagnosis, and disease genetics. Furthermore, the depth of response, evaluated using the level of MRD, has been established as a strong prognostic factor in several AML subgroups. In recent years, this rapidly evolving field has made the prognostic evaluation of AML more challenging. Traditional prognostic factors, established in cohorts of patients treated with standard intensive chemotherapy, are becoming less accurate as new effective therapies are emerging. The widespread availability of next-generation sequencing platforms has improved our knowledge of AML biology and, consequently, the recent ELN 2022 recommendations significantly expanded the role of new gene mutations. However, the impact of rare co-mutational patterns remains to be fully disclosed, and large international consortia such as the HARMONY project will hopefully be instrumental to this aim. Moreover, accumulating evidence suggests that clonal architecture plays a significant prognostic role. The integration of clinical, cytogenetic, and molecular factors is essential, but hierarchical methods are reaching their limit. Thus, innovative approaches are being extensively explored, including those based on \u201cknowledge banks\u201d. Indeed, more robust prognostic estimations can be obtained by matching each patient\u2019s genomic and clinical data with the ones derived from very large cohorts, but further improvements are needed.<\/jats:p>","DOI":"10.3390\/cancers15133512","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T01:57:09Z","timestamp":1688695029000},"page":"3512","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors"],"prefix":"10.3390","volume":"15","author":[{"given":"Eleonora","family":"Boscaro","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Oncology, Presidio Molinette, AOU Citt\u00e0 della Salute e della Scienza di Torino, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Urbino","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Oncology, Presidio Molinette, AOU Citt\u00e0 della Salute e della Scienza di Torino, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica Maria","family":"Catania","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Oncology, Presidio Molinette, AOU Citt\u00e0 della Salute e della Scienza di Torino, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Arrigo","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Oncology, Presidio Molinette, AOU Citt\u00e0 della Salute e della Scienza di Torino, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Secreto","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Oncology, Presidio Molinette, AOU Citt\u00e0 della Salute e della Scienza di Torino, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Olivi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Oncology, Presidio Molinette, AOU Citt\u00e0 della Salute e della Scienza di Torino, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"D\u2019Ardia","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Oncology, Presidio Molinette, AOU Citt\u00e0 della Salute e della Scienza di Torino, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Frairia","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Oncology, Presidio Molinette, AOU Citt\u00e0 della Salute e della Scienza di Torino, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Giai","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Oncology, Presidio Molinette, AOU Citt\u00e0 della Salute e della Scienza di Torino, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Freilone","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Oncology, Presidio Molinette, AOU Citt\u00e0 della Salute e della Scienza di Torino, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Ferrero","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesta","family":"Audisio","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Oncology, Presidio Molinette, AOU Citt\u00e0 della Salute e della Scienza di Torino, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1666-3100","authenticated-orcid":false,"given":"Marco","family":"Cerrano","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Oncology, Presidio Molinette, AOU Citt\u00e0 della Salute e della Scienza di Torino, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Urbino, I., Secreto, C., Olivi, M., Apolito, V., D\u2019Ardia, S., Frairia, C., Giai, V., Aydin, S., Freilone, R., and Dellacasa, C. (2021). Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021. Cancers, 13.","DOI":"10.3390\/cancers13205075"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019001239","article-title":"How I Treat Acute Myeloid Leukemia in the Era of New Drugs","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"R\u00f6llig, C., and Ossenkoppele, G.J. (2021). Acute Myeloid Leukemia, Springer International Publishing. Hematologic Malignancies.","DOI":"10.1007\/978-3-030-72676-8"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MOP.0000000000000855","article-title":"Pediatric acute myeloid leukemia: Updates on biology, risk stratification, and therapy","volume":"32","author":"Elgarten","year":"2020","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De Novo Acute Myeloid Leukemia: A Population-Based Study of Outcome in the United States Based on the Surveillance, Epidemiology, and End Results (SEER) Database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1038\/bcj.2014.10","article-title":"Incidence and Prognostic Significance of Karyotypic Subgroups in Older Patients with Acute Myeloid Leukemia: The Swedish Population-Based Experience","volume":"4","author":"Lazarevic","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and Acute Myeloid Leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and Acute Myeloid Leukemia: Real World Data on Decision to Treat and Outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Palmieri, R., Maurillo, L., Del Principe, M.I., Paterno, G., Walter, R.B., Venditti, A., and Buccisano, F. (2022). Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia. Cancers, 15.","DOI":"10.3390\/cancers15010136"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2012.303","article-title":"Consensus-Based Definition of Unfitness to Intensive and Non-Intensive Chemotherapy in Acute Myeloid Leukemia: A Project of SIE, SIES and GITMO Group on a New Tool for Therapy Decision Making","volume":"27","author":"Ferrara","year":"2013","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ajh.26805","article-title":"N-Terminal pro-Brain Natriuretic Peptide Is a Prognostic Marker for Response to Intensive Chemotherapy, Early Death, and Overall Survival in Acute Myeloid Leukemia","volume":"98","author":"Graf","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.2021013671","article-title":"Geriatric Assessment Predicts Nonfatal Toxicities and Survival for Intensively Treated Older Adults with AML","volume":"139","author":"Min","year":"2022","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Aydin, S., Passera, R., Cerrano, M., Giai, V., D\u2019Ardia, S., Iovino, G., Dellacasa, C.M., Audisio, E., and Busca, A. (2023). Combining the HCT-CI, G8, and AML-Score for Fitness Evaluation of Elderly Patients with Acute Myeloid Leukemia: A Single Center Analysis. Cancers, 15.","DOI":"10.3390\/cancers15041002"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.blre.2012.01.003","article-title":"Hyperleukocytosis, Leukostasis and Leukapheresis: Practice Management","volume":"26","author":"Ganzel","year":"2012","journal-title":"Blood Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/10428194.2019.1683735","article-title":"Predictors and Outcomes Associated with Hydroxyurea Sensitivity in Acute Myeloid Leukemia Patients with High Hyperleukocytosis","volume":"61","author":"Cerrano","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/ejh.13952","article-title":"Validation of National Early Warning Score and Quick Sequential (Sepsis-Related) Organ Failure Assessment in Acute Myeloid Leukaemia Patients Treated with Intensive Chemotherapy","volume":"110","author":"Frairia","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00277-023-05119-3","article-title":"Benefits of Dexamethasone on Early Outcomes in Patients with Acute Myeloid Leukemia with Hyperleukocytosis: A Propensity Score Matched Analysis","volume":"102","author":"Cerrano","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ajh.24737","article-title":"Long Term Impact of Hyperleukocytosis in Newly Diagnosed Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the EBMT","volume":"92","author":"Canaani","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/ejh.13073","article-title":"Hyperleukocytosis Is Associated with Distinct Genetic Alterations and Is an Independent Poor-Risk Factor in de novo Acute Myeloid Leukemia Patients","volume":"101","author":"Tien","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1200\/JCO.2016.67.5892","article-title":"Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980\u20132008","volume":"34","author":"Ganzel","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study","volume":"33","author":"Medeiros","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-020-0296-3","article-title":"Inferior Outcome of Allogeneic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia in First Complete Remission as Compared to de Novo Acute Myeloid Leukemia","volume":"10","author":"Schmaelter","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e1075","DOI":"10.1016\/j.clml.2022.08.010","article-title":"Characteristics and Outcomes of Secondary Acute Myeloid Leukemia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Multicenter Study from the Thai Acute Leukemia Study Group","volume":"22","author":"Chanswangphuwana","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Higgins, A., and Shah, M.V. (2020). Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia. Genes, 11.","DOI":"10.3390\/genes11070749"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute Myeloid Leukemia Ontogeny Is Defined by Distinct Somatic Mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Gurnari, C., Fabiani, E., Falconi, G., Travaglini, S., Ottone, T., Cristiano, A., and Voso, M.T. (2021). From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression. Biology, 10.","DOI":"10.3390\/biology10020128"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.22.00710","article-title":"Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria","volume":"41","author":"Gurnari","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/sj.leu.2403187","article-title":"Karyotype Is an Independent Prognostic Parameter in Therapy-Related Acute Myeloid Leukemia (t-AML): An Analysis of 93 Patients with t-AML in Comparison to 1091 Patients with de Novo AML","volume":"18","author":"Schoch","year":"2004","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.critrevonc.2019.03.003","article-title":"Challenges in the Diagnosis and Treatment of Secondary Acute Myeloid Leukemia","volume":"138","author":"Ossenkoppele","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/ajh.25814","article-title":"Comparison of Therapy-Related and de Novo Core Binding Factor Acute Myeloid Leukemia: A Bone Marrow Pathology Group Study","volume":"95","author":"Rogers","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3324\/haematol.2022.281233","article-title":"Characterization of Therapy-Related Acute Myeloid Leukemia: Increasing Incidence and Prognostic Implications","volume":"108","author":"Nilsson","year":"2023","journal-title":"Haematologica"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/cncr.29389","article-title":"Evolving Characteristics and Outcome of Secondary Acute Promyelocytic Leukemia (APL): A Prospective Analysis by the French-Belgian-Swiss APL Group","volume":"121","author":"Braun","year":"2015","journal-title":"Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/asheducation.V2016.1.24.088333","article-title":"Therapy-Related Myeloid Neoplasms: Does Knowing the Origin Help to Guide Treatment?","volume":"2016","author":"Heuser","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 Alterations in Acute Myeloid Leukemia with Complex Karyotype Correlate with Specific Copy Number Alterations, Monosomal Karyotype, and Dismal Outcome","volume":"119","author":"Schlenk","year":"2012","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2022-164739","article-title":"Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification","volume":"140","author":"Hochman","year":"2022","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating Morphologic, Clinical, and Genomic Data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and Management of AML in Adults: 2022 Recommendations from an International Expert Panel on Behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/bloodadvances.2017008227","article-title":"Treated Secondary Acute Myeloid Leukemia: A Distinct High-Risk Subset of AML with Adverse Prognosis","volume":"1","author":"Boddu","year":"2017","journal-title":"Blood Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"On behalf of the National Cancer Research Institute Adult Leukaemia Working Group Refinement of Cytogenetic Classification in Acute Myeloid Leukemia: Determination of Prognostic Significance of Rare Recurring Chromosomal Abnormalities among 5876 Younger Adult Patients Treated in the United Kingdom Medical Research Council Trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic Analysis Predicts Outcome of Preremission and Postremission Therapy in Adult Acute Myeloid Leukemia: A Southwest Oncology Group\/Eastern Cooperative Oncology Group Study","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","article-title":"Pretreatment Cytogenetic Abnormalities Are Predictive of Induction Success, Cumulative Incidence of Relapse, and Overall Survival in Adult Patients with de Novo Acute Myeloid Leukemia: Results from Cancer and Leukemia Group B (CALGB 8461)Presented in Part at the 43rd Annual Meeting of the American Society of Hematology, Orlando, FL, December 10, 2001, and Published in Abstract Form.59","volume":"100","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of Acute Promyelocytic Leukemia: Updated Recommendations from an Expert Panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/EDBK_199519","article-title":"Acute Myeloid Leukemia: The Good, the Bad, and the Ugly","volume":"38","author":"Kuykendall","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.hoc.2011.09.018","article-title":"Diagnostic and Prognostic Value of Cytogenetics in Acute Myeloid Leukemia","volume":"25","author":"Grimwade","year":"2011","journal-title":"Hematol.\/Oncol. Clin. N. Am."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","article-title":"Prospective Evaluation of Gene Mutations and Minimal Residual Disease in Patients with Core Binding Factor Acute Myeloid Leukemia","volume":"121","author":"Jourdan","year":"2013","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41375-019-0697-0","article-title":"The Clinical Mutatome of Core Binding Factor Leukemia","volume":"34","author":"Opatz","year":"2020","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1038\/bcj.2016.51","article-title":"Next-Generation Sequencing with a Myeloid Gene Panel in Core-Binding Factor AML Showed KIT Activation Loop and TET2 Mutations Predictive of Outcome","volume":"6","author":"Cher","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1182\/bloodadvances.2020003605","article-title":"Secondary Cytogenetic Abnormalities in Core-Binding Factor AML Harboring Inv(16) vs t(8;21)","volume":"5","author":"Han","year":"2021","journal-title":"Blood Adv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2004.03.012","article-title":"Individual Patient Data-Based Meta-Analysis of Patients Aged 16 to 60 Years with Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup","volume":"22","author":"Schlenk","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1038\/s41375-020-0806-0","article-title":"Validation and Refinement of the Revised 2017 European LeukemiaNet Genetic Risk Stratification of Acute Myeloid Leukemia","volume":"34","author":"Herold","year":"2020","journal-title":"Leukemia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1038\/s41375-018-0158-1","article-title":"Response Kinetics and Factors Predicting Survival in Core-Binding Factor Leukemia","volume":"32","author":"Boddu","year":"2018","journal-title":"Leukemia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/bloodadvances.2019000709","article-title":"Prospective Evaluation of Prognostic Impact of KIT Mutations on Acute Myeloid Leukemia with RUNX1-RUNX1T1 and CBFB-MYH11","volume":"4","author":"Ishikawa","year":"2020","journal-title":"Blood Adv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2012-05-431486","article-title":"Secondary Genetic Lesions in Acute Myeloid Leukemia with Inv(16) or t(16;16): A Study of the German-Austrian AML Study Group (AMLSG)","volume":"121","author":"Paschka","year":"2013","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1182\/blood-2018-05-852822","article-title":"Genomic Landscape and Clonal Evolution of Acute Myeloid Leukemia with t(8;21): An International Study on 331 Patients","volume":"133","author":"Christen","year":"2019","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","article-title":"Unified Classification and Risk-Stratification in Acute Myeloid Leukemia","volume":"13","author":"Tazi","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/sj.leu.2404188","article-title":"Incidence and Prognostic Impact of C-Kit, FLT3, and Ras Gene Mutations in Core Binding Factor Acute Myeloid Leukemia (CBF-AML)","volume":"20","author":"Boissel","year":"2006","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1200\/JCO.2006.06.9500","article-title":"Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia with Inv(16) and t(8;21): A Cancer and Leukemia Group B Study","volume":"24","author":"Paschka","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood.2019001425","article-title":"Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(Q22;Q22.1): Results from the AML Study Group","volume":"134","author":"Agrawal","year":"2019","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Chen, W., Xie, H., Wang, H., Chen, L., Sun, Y., Chen, Z., and Li, Q. (2016). Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0146614"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2015.61.1947","article-title":"Clinical Impact of Additional Cytogenetic Aberrations, CKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-M\u00fcnster Study Group","volume":"33","author":"Klein","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/blood-2018-03-837781","article-title":"Clonal Interference of Signaling Mutations Worsens Prognosis in Core-Binding Factor Acute Myeloid Leukemia","volume":"132","author":"Itzykson","year":"2018","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3324\/haematol.2021.278645","article-title":"Characteristics and Outcome of Patients with Core-Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaborative Study","volume":"107","author":"Kayser","year":"2022","journal-title":"Haematologica"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1002\/cncr.25670","article-title":"Prognostic Value of FLT3 Mutations among Different Cytogenetic Subgroups in Acute Myeloid Leukemia","volume":"117","author":"Santos","year":"2011","journal-title":"Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/leu.2017.213","article-title":"The MLL Recombinome of Acute Leukemias in 2017","volume":"32","author":"Meyer","year":"2018","journal-title":"Leukemia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/bjh.12852","article-title":"Acute Myeloid Leukaemia (AML) with t(6;9)(P23;Q34) Is Associated with Poor Outcome in Childhood AML Regardless of FLT3-ITD Status: A Report from the Children\u2019s Oncology Group","volume":"166","author":"Tarlock","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/bjh.16433","article-title":"Allogeneic Stem Cell Transplantation in AML with t(6;9)(P23;Q34);DEK-NUP214 Shows a Favourable Outcome When Performed in First Complete Remission","volume":"189","author":"Labopin","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.2010.29.2771","article-title":"Clinical, Molecular, and Prognostic Significance of WHO Type Inv(3)(Q21q26.2)\/t(3;3)(Q21;Q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia","volume":"28","author":"Lugthart","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Richard-Carpentier, G., Rausch, C.R., Sasaki, K., Hammond, D., Morita, K., Takahashi, K., Tang, G., Kanagal-Shamanna, R., Bhalla, K., and Dinardo, C.D. (2023). Characteristics and Clinical Outcomes of Patients with Acute Myeloid Leukemia with Inv(3)(Q21q26.2) or t(3;3)(Q21;Q26.2). Haematologica.","DOI":"10.3324\/haematol.2022.282030"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood.2019003701","article-title":"Atypical 3q26\/MECOM Rearrangements Genocopy Inv(3)\/t(3;3) in Acute Myeloid Leukemia","volume":"136","author":"Ottema","year":"2020","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00277-016-2721-z","article-title":"BCR-ABL-Positive Acute Myeloid Leukemia: A New Entity? Analysis of Clinical and Molecular Features","volume":"95","author":"Neuendorff","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/bloodadvances.2018015594","article-title":"BCR-ABL+ Acute Myeloid Leukemia: Are We Always Dealing with a High-Risk Disease?","volume":"2","author":"Neuendorff","year":"2018","journal-title":"Blood Adv."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ajh.24928","article-title":"Relatively Favorable Outcome after Allogeneic Stem Cell Transplantation for BCR-ABL1-Positive AML: A Survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"93","author":"Lazarevic","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"107002","DOI":"10.1016\/j.leukres.2022.107002","article-title":"Molecular Genetic Characterization of Philadelphia Chromosome-Positive Acute Myeloid Leukemia","volume":"124","author":"Zhou","year":"2023","journal-title":"Leuk. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/bjh.17336","article-title":"Characteristics and Outcome of Patients with Acute Myeloid Leukaemia and t(8;16)(P11;P13): Results from an International Collaborative Study*","volume":"192","author":"Kayser","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/cncr.30220","article-title":"Changes in Cytogenetics and Molecular Genetics in Acute Myeloid Leukemia from Childhood to Adult Age Groups","volume":"122","author":"Creutzig","year":"2016","journal-title":"Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1038\/bcj.2015.114","article-title":"Karyotype Complexity and Prognosis in Acute Myeloid Leukemia","volume":"6","author":"Mohr","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2011-10-385781","article-title":"Prognostic Value of Monosomal Karyotype in Comparison to Complex Aberrant Karyotype in Acute Myeloid Leukemia: A Study on 824 Cases with Aberrant Karyotype","volume":"119","author":"Haferlach","year":"2012","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/gcc.20193","article-title":"Acute Myeloid Leukemia with a Complex Aberrant Karyotype Is a Distinct Biological Entity Characterized by Genomic Imbalances and a Specific Gene Expression Profile","volume":"43","author":"Schoch","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41375-019-0390-3","article-title":"Complex Karyotype in de Novo Acute Myeloid Leukemia: Typical and Atypical Subtypes Differ Molecularly and Clinically","volume":"33","author":"Eisfeld","year":"2019","journal-title":"Leukemia"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1200\/JCO.2008.16.0259","article-title":"Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis than a Complex Karyotype","volume":"26","author":"Breems","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2010-02-270330","article-title":"Prognostic Impact of Monosomal Karyotype in Young Adult and Elderly Acute Myeloid Leukemia: The Southwest Oncology Group (SWOG) Experience","volume":"116","author":"Medeiros","year":"2010","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/ajh.24091","article-title":"Prognostic Significance of High Hyperdiploid and Triploid\/Tetraploid Adult Acute Myeloid Leukemia","volume":"90","author":"Lazarevic","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3324\/haematol.2022.281137","article-title":"Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4","volume":"108","author":"Kayser","year":"2023","journal-title":"Haematologica"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/leu.2013.198","article-title":"Hyperdiploidy with 49-65 Chromosomes Represents a Heterogeneous Cytogenetic Subgroup of Acute Myeloid Leukemia with Differential Outcome","volume":"28","author":"Chilton","year":"2014","journal-title":"Leukemia"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","article-title":"Molecular Landscape of Acute Myeloid Leukemia in Younger Adults and Its Clinical Relevance","volume":"127","author":"Grimwade","year":"2016","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1182\/blood-2010-05-283648","article-title":"FLT3 Internal Tandem Duplication Associates with Adverse Outcome and Gene- and MicroRNA-Expression Signatures in Patients 60 Years of Age or Older with Primary Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study","volume":"116","author":"Whitman","year":"2010","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/s41375-018-0068-2","article-title":"Mutation Patterns Identify Adult Patients with de Novo Acute Myeloid Leukemia Aged 60 Years or Older Who Respond Favorably to Standard Chemotherapy: An Analysis of Alliance Studies","volume":"32","author":"Eisfeld","year":"2018","journal-title":"Leukemia"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.3324\/haematol.2018.191809","article-title":"Impact of FLT3-ITD Length on Prognosis of Acute Myeloid Leukemia","volume":"104","author":"Liu","year":"2019","journal-title":"Haematologica"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2007-05-091215","article-title":"Prognostic Relevance of FLT3-TKD Mutations in AML: The Combination Matters\u2014An Analysis of 3082 Patients","volume":"111","author":"Bacher","year":"2008","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2006-04-015826","article-title":"FLT3 Tyrosine Kinase Domain Mutations Are Biologically Distinct from and Have a Significantly More Favorable Prognosis than FLT3 Internal Tandem Duplications in Patients with Acute Myeloid Leukemia","volume":"110","author":"Mead","year":"2007","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/bloodadvances.2017009019","article-title":"Co-Occurrence of FLT3-TKD and NPM1 Mutations Defines a Highly Favorable Prognostic AML Group","volume":"1","author":"Boddu","year":"2017","journal-title":"Blood Adv."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1182\/blood-2005-08-3167","article-title":"Prevalence and Prognostic Impact of NPM1 Mutations in 1485 Adult Patients with Acute Myeloid Leukemia (AML)","volume":"107","author":"Thiede","year":"2006","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1182\/blood-2010-12-327072","article-title":"The FLT3ITD MRNA Level Has a High Prognostic Impact in NPM1 Mutated, but Not in NPM1 Unmutated, AML with a Normal Karyotype","volume":"119","author":"Schneider","year":"2012","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1182\/blood-2018-01-828467","article-title":"High NPM1 Mutant Allele Burden at Diagnosis Predicts Unfavorable Outcomes in de Novo AML","volume":"131","author":"Patel","year":"2018","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Wang, Y., Quesada, A.E., Zuo, Z., Medeiros, L.J., Yin, C.C., Li, S., Xu, J., Borthakur, G., Li, Y., and Yang, C. (2023). The Impact of Mutation of Myelodysplasia-Related Genes in De Novo Acute Myeloid Leukemia Carrying NPM1 Mutation. Cancers, 15.","DOI":"10.3390\/cancers15010198"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2009-01-197871","article-title":"AML with Mutated NPM1 Carrying a Normal or Aberrant Karyotype Show Overlapping Biologic, Pathologic, Immunophenotypic, and Prognostic Features","volume":"114","author":"Haferlach","year":"2009","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1200\/JCO.19.00416","article-title":"Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts","volume":"37","author":"Angenendt","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1182\/blood.2022018108","article-title":"Overlapping Features of Therapy-Related and de Novo NPM1-Mutated AML","volume":"141","author":"Othman","year":"2023","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1200\/JCO.2004.06.060","article-title":"CEBPA Mutations in Younger Adults with Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating Mutations","volume":"22","author":"Schlenk","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.1182\/blood-2008-12-194704","article-title":"The Favorable Impact of CEBPA Mutations in Patients with Acute Myeloid Leukemia Is Only Observed in the Absence of Associated Cytogenetic Abnormalities and FLT3 Internal Duplication","volume":"113","author":"Renneville","year":"2009","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood-2010-09-307280","article-title":"Prognostic Impact, Concurrent Genetic Mutations, and Gene Expression Features of AML with CEBPA Mutations in a Cohort of 1182 Cytogenetically Normal AML Patients: Further Evidence for CEBPA Double Mutant AML as a Distinctive Disease Entity","volume":"117","author":"Taskesen","year":"2011","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1182\/blood.2020009680","article-title":"CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia: Differential Impact of BZIP and TAD Mutations on Outcome","volume":"139","author":"Taube","year":"2022","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/bloodadvances.2021004292","article-title":"Prognostic Impact of CEBPA BZIP Domain Mutation in Acute Myeloid Leukemia","volume":"6","author":"Wakita","year":"2022","journal-title":"Blood Adv."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1182\/bloodadvances.2018016840","article-title":"Genetic Heterogeneity of Cytogenetically Normal AML with Mutations of CEBPA","volume":"2","author":"Konstandin","year":"2018","journal-title":"Blood Adv."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.3324\/haematol.2018.189043","article-title":"Concomitant WT1 Mutations Predict Poor Prognosis in Acute Myeloid Leukemia Patients with Double Mutant CEBPA","volume":"103","author":"Tien","year":"2018","journal-title":"Haematologica"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 Mutation Defines a Unique Subgroup within Complex Karyotype de Novo and Therapy-Related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular Characterization of Mutant TP53 Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00277-022-04766-2","article-title":"Comparison of Acute Myeloid Leukemia and Myelodysplastic Syndromes with TP53 Aberrations","volume":"101","author":"Dutta","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 Allelic State for Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2022-163044","article-title":"Prognostic Impact of Monoallelic Versus Biallelic TP53 Alterations in Intensively-Treated Adults AML Patients: A Retrospective Study from the ALFA Group","volume":"140","author":"Fenwarth","year":"2022","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2022-162913","article-title":"A Clinically Practicable Approach to Predict TP53 Allelic Configurations in Myeloid Neoplasia","volume":"140","author":"Bahaj","year":"2022","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","article-title":"Prognostic and Therapeutic Impacts of Mutant TP53 Variant Allelic Frequency in Newly Diagnosed Acute Myeloid Leukemia","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/leu.2014.55","article-title":"Comprehensive Analysis of Genetic Alterations and Their Prognostic Impacts in Adult Acute Myeloid Leukemia Patients","volume":"28","author":"Kihara","year":"2014","journal-title":"Leukemia"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/leu.2016.126","article-title":"RUNX1 Mutations in Acute Myeloid Leukemia Are Associated with Distinct Clinico-Pathologic and Genetic Features","volume":"30","author":"Gaidzik","year":"2016","journal-title":"Leukemia"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3324\/haematol.2012.064667","article-title":"RUNX1 Mutations in Cytogenetically Normal Acute Myeloid Leukemia Are Associated with a Poor Prognosis and Up-Regulation of Lymphoid Genes","volume":"97","author":"Greif","year":"2012","journal-title":"Haematologica"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","article-title":"Spectrum and Prognostic Relevance of Driver Gene Mutations in Acute Myeloid Leukemia","volume":"128","author":"Metzeler","year":"2016","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2012.262","article-title":"ASXL1 Exon 12 Mutations Are Frequent in AML with Intermediate Risk Karyotype and Are Independently Associated with an Adverse Outcome","volume":"27","author":"Schnittger","year":"2013","journal-title":"Leukemia"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3324\/haematol.2011.051532","article-title":"Acquired Mutations in ASXL1 in Acute Myeloid Leukemia: Prevalence and Prognostic Value","volume":"97","author":"Pratcorona","year":"2012","journal-title":"Haematologica"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and Management of AML in Adults: 2017 ELN Recommendations from an International Expert Panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/bloodadvances.2020003159","article-title":"Real-Life Experience with CPX-351 and Impact on the Outcome of High-Risk AML Patients: A Multicentric French Cohort","volume":"5","author":"Chiche","year":"2021","journal-title":"Blood Adv."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Othman, J., Wilhelm-Benartzi, C.S., Dillon, R., Knapper, S., Freeman, S.D., Batten, L.M., Canham, J., Hinson, E.L., Wych, J., and Betteridge, S. (2023). A Randomised Comparison of CPX-351 and FLAG-Ida in Adverse Karyotype AML and High-Risk MDS: The UK NCRI AML19 Trial. Blood Adv.","DOI":"10.1182\/bloodadvances.2023010276"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3324\/haematol.2022.280801","article-title":"The Clinical Impact of the Molecular Landscape of Acute Myeloid Leukemia","volume":"108","author":"Kayser","year":"2023","journal-title":"Haematologica"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of Acute Myeloid Leukemia Diagnosis and Pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A Mutations in Acute Myeloid Leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.2011.35.4894","article-title":"Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia","volume":"29","author":"Thol","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbmt.2015.07.030","article-title":"DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation","volume":"22","author":"Ahn","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cancergen.2019.10.006","article-title":"Cytogenetic and Molecular Genetic Characterization of KMT2A-PTD Positive Acute Myeloid Leukemia in Comparison to KMT2A-Rearranged Acute Myeloid Leukemia","volume":"240","author":"Vetro","year":"2020","journal-title":"Cancer Genet."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1097\/HS9.0000000000000181","article-title":"The Landscape of KMT2A-PTD AML: Concurrent Mutations, Gene Expression Signatures, and Clinical Outcome","volume":"3","author":"Hinai","year":"2019","journal-title":"Hemasphere"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1200\/JCO.2007.15.2058","article-title":"Wilms\u2019 Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults with Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study","volume":"26","author":"Paschka","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1182\/blood-2008-10-183392","article-title":"Prognostic Impact of WT1 Mutations in Cytogenetically Normal Acute Myeloid Leukemia: A Study of the German-Austrian AML Study Group","volume":"113","author":"Gaidzik","year":"2009","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Sargas, C., Ayala, R., Larr\u00e1yoz, M.J., Chill\u00f3n, M.C., Carrillo-Cruz, E., Bilbao-Sieyro, C., Prados de la Torre, E., Mart\u00ednez-Cuadr\u00f3n, D., Rodr\u00edguez-Veiga, R., and Boluda, B. (2023). Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry. Cancers, 15.","DOI":"10.3390\/cancers15020438"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41375-020-0920-z","article-title":"The Clinical Impact of PTPN11 Mutations in Adults with Acute Myeloid Leukemia","volume":"35","author":"Alfayez","year":"2021","journal-title":"Leukemia"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1182\/bloodadvances.2021004631","article-title":"Impact of PTPN11 Mutations on Clinical Outcome Analyzed in 1529 Patients with Acute Myeloid Leukemia","volume":"5","author":"Stasik","year":"2021","journal-title":"Blood Adv."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1182\/bloodadvances.2021006242","article-title":"Molecular, Clinical, and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia","volume":"6","author":"Fobare","year":"2022","journal-title":"Blood Adv."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/leu.2008.388","article-title":"AML with Translocation t(8;16)(P11;P13) Demonstrates Unique Cytomorphological, Cytogenetic, Molecular and Prognostic Features","volume":"23","author":"Haferlach","year":"2009","journal-title":"Leukemia"},{"key":"ref_142","first-page":"2156","article-title":"CREBBP Alterations Are Associated with a Poor Prognosis in de Novo AML","volume":"141","author":"Lamble","year":"2023","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.3324\/haematol.2018.207118","article-title":"A Phase II Study of Guadecitabine in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia after Azacitidine Failure","volume":"104","author":"Renneville","year":"2019","journal-title":"Haematologica"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2021015328","article-title":"Prognostic Impact of DDX41 Germline Mutations in Intensively Treated Acute Myeloid Leukemia Patients: An ALFA-FILO Study","volume":"140","author":"Duployez","year":"2022","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3324\/haematol.2018.201053","article-title":"A Systematic Literature Review and Meta-Analysis of Minimal Residual Disease as a Prognostic Indicator in Adult B-Cell Acute Lymphoblastic Leukemia","volume":"104","author":"Bassan","year":"2019","journal-title":"Haematologica"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.3324\/haematol.2022.282034","article-title":"The Present and Future of Measurable Residual Disease Testing in Acute Myeloid Leukemia","volume":"107","author":"Blachly","year":"2022","journal-title":"Haematologica"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/Measurable Residual Disease in AML: A Consensus Document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"890871","DOI":"10.3389\/fonc.2022.890871","article-title":"MRD in Venetoclax-Based Treatment for AML: Does It Really Matter?","volume":"12","author":"Bernardi","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable Residual Disease Response and Prognosis in Treatment-Na\u00efve Acute Myeloid Leukemia with Venetoclax and Azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/bloodadvances.2020003717","article-title":"Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia","volume":"5","author":"Maiti","year":"2021","journal-title":"Blood Adv."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","article-title":"Significance of Minimal Residual Disease before Myeloablative Allogeneic Hematopoietic Cell Transplantation for AML in First and Second Complete Remission","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/bmt.2014.9","article-title":"Pre-Transplant MRD Predicts Outcome Following Reduced-Intensity and Myeloablative Allogeneic Hemopoietic SCT in AML","volume":"49","author":"Anthias","year":"2014","journal-title":"Bone Marrow Transpl."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal Residual Disease Prior to Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Meta-Analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","article-title":"Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Pollyea","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood.2019002697","article-title":"Impact of NPM1\/FLT3-ITD Genotypes Defined by the 2017 European LeukemiaNet in Patients with Acute Myeloid Leukemia","volume":"135","author":"Thiede","year":"2020","journal-title":"Blood"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/bloodadvances.2022009010","article-title":"Comparison and Validation of the 2022 European LeukemiaNet Guidelines in Acute Myeloid Leukemia","volume":"7","author":"Lachowiez","year":"2023","journal-title":"Blood Adv."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ajh.26892","article-title":"Validation of the Prognostic Significance of the 2022 European LeukemiaNet Risk Stratification System in Intensive Chemotherapy Treated Aged 18 to 65\u2009Years Patients with de Novo Acute Myeloid Leukemia","volume":"98","author":"Lo","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","article-title":"Validation and Refinement of the 2022 European LeukemiaNet Genetic Risk Stratification of Acute Myeloid Leukemia","volume":"37","author":"Rausch","year":"2023","journal-title":"Leukemia"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41375-023-01846-8","article-title":"Outcome Prediction by the 2022 European LeukemiaNet Genetic-Risk Classification for Adults with Acute Myeloid Leukemia: An Alliance Study","volume":"37","author":"Kohlschmidt","year":"2023","journal-title":"Leukemia"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood-2022-169509","article-title":"ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Na\u00efve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine","volume":"140","author":"Pratz","year":"2022","journal-title":"Blood"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-019-0734-5","article-title":"Role of MicroRNAs, CircRNAs and Long Noncoding RNAs in Acute Myeloid Leukemia","volume":"12","author":"Liu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_163","first-page":"3342","article-title":"Long Noncoding RNA SNHG5 Is Up-Regulated and Serves as a Potential Prognostic Biomarker in Acute Myeloid Leukemia","volume":"22","author":"Li","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"18679","DOI":"10.1073\/pnas.1422050112","article-title":"Expression and Prognostic Impact of LncRNAs in Acute Myeloid Leukemia","volume":"111","author":"Garzon","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/leu.2017.210","article-title":"A Four-Gene LincRNA Expression Signature Predicts Risk in Multiple Cohorts of Acute Myeloid Leukemia Patients","volume":"32","author":"Beck","year":"2018","journal-title":"Leukemia"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1200\/JCO.22.01114","article-title":"Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia","volume":"41","author":"Farrar","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa074256","article-title":"MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia","volume":"358","author":"Marcucci","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1200\/JCO.2012.45.6228","article-title":"Clinical Role of MicroRNAs in Cytogenetically Normal Acute Myeloid Leukemia: MiR-155 Upregulation Independently Identifies High-Risk Patients","volume":"31","author":"Marcucci","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/leu.2013.281","article-title":"MicroRNA Expression at Diagnosis Adds Relevant Prognostic Information to Molecular Categorization in Patients with Intermediate-Risk Cytogenetic Acute Myeloid Leukemia","volume":"28","author":"Brunet","year":"2014","journal-title":"Leukemia"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/s41375-018-0033-0","article-title":"MYC-Containing Amplicons in Acute Myeloid Leukemia: Genomic Structures, Evolution, and Transcriptional Consequences","volume":"32","author":"Tolomeo","year":"2018","journal-title":"Leukemia"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","article-title":"DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia","volume":"17","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2009-03-211003","article-title":"Quantitative DNA Methylation Predicts Survival in Adult Acute Myeloid Leukemia","volume":"115","author":"Bullinger","year":"2010","journal-title":"Blood"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1200\/JCO.2013.50.6337","article-title":"Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score","volume":"32","author":"Marcucci","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1182\/blood-2011-01-332353","article-title":"Prognostic DNA Methylation Patterns in Cytogenetically Normal Acute Myeloid Leukemia Are Predefined by Stem Cell Chromatin Marks","volume":"118","author":"Deneberg","year":"2011","journal-title":"Blood"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/leu.2013.362","article-title":"Epimutations Mimic Genomic Mutations of DNMT3A in Acute Myeloid Leukemia","volume":"28","author":"Jost","year":"2014","journal-title":"Leukemia"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e87323","DOI":"10.1172\/jci.insight.87323","article-title":"A Clinical Measure of DNA Methylation Predicts Outcome in de Novo Acute Myeloid Leukemia","volume":"1","author":"Luskin","year":"2016","journal-title":"JCI Insight"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1002\/ajh.24597","article-title":"Validation of a Clinical Assay of Multi-Locus DNA Methylation for Prognosis of Newly Diagnosed AML","volume":"92","author":"DiNardo","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1182\/blood-2008-02-134411","article-title":"An 86-Probe-Set Gene-Expression Signature Predicts Survival in Cytogenetically Normal Acute Myeloid Leukemia","volume":"112","author":"Metzeler","year":"2008","journal-title":"Blood"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cell.2015.05.047","article-title":"Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells That Correlate with Prognosis","volume":"162","author":"Levine","year":"2015","journal-title":"Cell"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm.2415","article-title":"Stem Cell Gene Expression Programs Influence Clinical Outcome in Human Leukemia","volume":"17","author":"Eppert","year":"2011","journal-title":"Nat. Med."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature20598","article-title":"A 17-Gene Stemness Score for Rapid Determination of Risk in Acute Leukaemia","volume":"540","author":"Ng","year":"2016","journal-title":"Nature"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41375-018-0227-5","article-title":"The Stem Cell-Associated Gene Expression Signature Allows Risk Stratification in Pediatric Acute Myeloid Leukemia","volume":"33","author":"Duployez","year":"2019","journal-title":"Leukemia"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3324\/haematol.2019.225003","article-title":"Mutations Associated with a 17-Gene Leukemia Stem Cell Score and Its Prognostic Relevance in the Context of the European LeukemiaNet Classification for Acute Myeloid Leukemia","volume":"105","author":"Bill","year":"2019","journal-title":"Haematologica"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1182\/bloodadvances.2023010155","article-title":"LSC17 Score Complements Genetics and Measurable Residual Disease in Acute Myeloid Leukemia: An ALFA Study","volume":"7","author":"Vasseur","year":"2023","journal-title":"Blood Adv."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood.V91.12.4480","article-title":"Pgp and MRP Activities Using Calcein-AM Are Prognostic Factors in Adult Acute Myeloid Leukemia Patients","volume":"91","author":"Legrand","year":"1998","journal-title":"Blood"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1046\/j.0007-1048.2002.03350.x","article-title":"High Multidrug Resistance Protein Activity in Acute Myeloid Leukaemias Is Associated with Poor Response to Chemotherapy and Reduced Patient Survival","volume":"116","author":"Laupeze","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1365-2141.2000.02315.x","article-title":"High Bax Expression Is a Good Prognostic Indicator in Acute Myeloid Leukaemia","volume":"111","author":"Ong","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1182\/blood-2002-06-1714","article-title":"Amount of Spontaneous Apoptosis Detected by Bax\/Bcl-2 Ratio Predicts Outcome in Acute Myeloid Leukemia (AML)","volume":"101","author":"Venditti","year":"2003","journal-title":"Blood"},{"key":"ref_189","first-page":"934","article-title":"Combined Analysis of Bcl-2 and MDR1 Proteins in 256 Cases of Acute Myeloid Leukemia","volume":"89","author":"Venditti","year":"2004","journal-title":"Haematologica"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1182\/blood-2012-02-409888","article-title":"Survivin Is Highly Expressed in CD34+38\u2212 Leukemic Stem\/Progenitor Cells and Predicts Poor Clinical Outcomes in AML","volume":"120","author":"Carter","year":"2012","journal-title":"Blood"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1182\/blood-2007-10-119438","article-title":"Functional Proteomic Profiling of AML Predicts Response and Survival","volume":"113","author":"Kornblau","year":"2009","journal-title":"Blood"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccell.2022.02.006","article-title":"The Proteogenomic Subtypes of Acute Myeloid Leukemia","volume":"40","author":"Jayavelu","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","article-title":"Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML","volume":"151","author":"Vo","year":"2012","journal-title":"Cell"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"e819","DOI":"10.1097\/HS9.0000000000000819","article-title":"Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively","volume":"7","author":"Pacchiardi","year":"2023","journal-title":"HemaSphere"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"7244","DOI":"10.1038\/s41467-021-27472-5","article-title":"Clonal Architecture Predicts Clinical Outcomes and Drug Sensitivity in Acute Myeloid Leukemia","volume":"12","author":"Benard","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-Cell Mutation Analysis of Clonal Evolution in Myeloid Malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood.2020010165","article-title":"Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH-Mutated AML: An ALFA Study","volume":"137","author":"Duchmann","year":"2021","journal-title":"Blood"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2013.50.7921","article-title":"Clonal Heterogeneity as Detected by Metaphase Karyotyping Is an Indicator of Poor Prognosis in Acute Myeloid Leukemia","volume":"31","author":"Bochtler","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/nm.4125","article-title":"Distinct Evolution and Dynamics of Epigenetic and Genetic Heterogeneity in Acute Myeloid Leukemia","volume":"22","author":"Li","year":"2016","journal-title":"Nat. Med."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41375-020-0932-8","article-title":"Clonal Dominance Is an Adverse Prognostic Factor in Acute Myeloid Leukemia Treated with Intensive Chemotherapy","volume":"35","author":"Cerrano","year":"2021","journal-title":"Leukemia"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1038\/s41467-020-19119-8","article-title":"Clonal Evolution of Acute Myeloid Leukemia Revealed by High-Throughput Single-Cell Genomics","volume":"11","author":"Morita","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Duchmann, M., Laplane, L., and Itzykson, R. (2021). Clonal Architecture and Evolutionary Dynamics in Acute Myeloid Leukemias. Cancers, 13.","DOI":"10.3390\/cancers13194887"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.molcel.2019.01.009","article-title":"Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing","volume":"73","author":"Buck","year":"2019","journal-title":"Mol. Cell."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41408-022-00734-1","article-title":"Hematopoietic Differentiation at Single-Cell Resolution in NPM1-Mutated AML","volume":"12","author":"Duchmann","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic Stem Cell Transplantation for Patients with AML in First Complete Remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1200\/JCO.2013.52.3480","article-title":"Combined Molecular and Clinical Prognostic Index for Relapse and Survival in Cytogenetically Normal Acute Myeloid Leukemia","volume":"32","author":"Pastore","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.3324\/haematol.2014.115576","article-title":"Impact of Additional Genetic Alterations on the Outcome of Patients with NPM1-Mutated Cytogenetically Normal Acute Myeloid Leukemia","volume":"100","author":"Peterlin","year":"2015","journal-title":"Haematologica"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1182\/blood.2019003339","article-title":"Co-Occurrence of DNMT3A, NPM1, FLT3 Mutations Identifies a Subset of Acute Myeloid Leukemia with Adverse Prognosis","volume":"135","author":"Bezerra","year":"2020","journal-title":"Blood"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2022-167138","article-title":"Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML\u2014Results of the European Harmony Alliance","volume":"140","author":"Gastone","year":"2022","journal-title":"Blood"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/ng.3756","article-title":"Precision Oncology for Acute Myeloid Leukemia Using a Knowledge Bank Approach","volume":"49","author":"Gerstung","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2018-03-840348","article-title":"Validation of the Prognostic Value of the Knowledge Bank Approach to Determine AML Prognosis in Real Life","volume":"132","author":"Huet","year":"2018","journal-title":"Blood"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13045-021-01118-x","article-title":"Precision Oncology in AML: Validation of the Prognostic Value of the Knowledge Bank Approach and Suggestions for Improvement","volume":"14","author":"Bill","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1182\/blood.2020005524","article-title":"A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia","volume":"137","author":"Fenwarth","year":"2021","journal-title":"Blood"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.2021011103","article-title":"Genetic Identification of Patients with AML Older than 60 Years Achieving Long-Term Survival with Intensive Chemotherapy","volume":"138","author":"Itzykson","year":"2021","journal-title":"Blood"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1182\/bloodadvances.2021006689","article-title":"Validation of ALFA 1200 Score in Patients with AML >60 Years Treated with Double Nucleoside-Based Low-Intensity Therapy","volume":"6","author":"Venugopal","year":"2022","journal-title":"Blood Adv."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11912-019-0764-8","article-title":"New Treatment Options for Acute Myeloid Leukemia in 2019","volume":"21","author":"Cerrano","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"5656","DOI":"10.1002\/cam4.5408","article-title":"Real-Life Challenges Using Personalized Prognostic Scoring Systems in Acute Myeloid Leukemia","volume":"12","author":"Calleja","year":"2023","journal-title":"Cancer Med."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"E382","DOI":"10.1002\/ajh.26653","article-title":"Outcome Prediction by the Knowledge Bank Approach in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation","volume":"97","author":"Herrmann","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","article-title":"Functional Precision Oncology: Testing Tumors with Drugs to Identify Vulnerabilities and Novel Combinations","volume":"40","author":"Letai","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional Genomic Landscape of Acute Myeloid Leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41408-022-00689-3","article-title":"A Multiparametric Niche-like Drug Screening Platform in Acute Myeloid Leukemia","volume":"12","author":"Pasanisi","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"100679","DOI":"10.1016\/j.blre.2020.100679","article-title":"Selection of Initial Therapy for Newly-Diagnosed Adult Acute Myeloid Leukemia: Limitations of Predictive Models","volume":"44","author":"Walter","year":"2020","journal-title":"Blood Rev."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/13\/3512\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:07:09Z","timestamp":1760126829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/13\/3512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":222,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["cancers15133512"],"URL":"https:\/\/doi.org\/10.3390\/cancers15133512","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]}}}